Facebook
Twitter
LinkedIn
Forward2025 Oklahoma Thoracic Oncology Conference
This CME-accredited activity, the 2025 Oklahoma Thoracic Oncology Conference, brings together leaders in the field of thoracic oncology to provide an extensive overview of both current and emerging strategies for managing lung cancer (NSCLC and SCLC). The primary aim of this conference is to enhance the knowledge and competence of participants, enabling them to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for lung cancer patients. The program includes detailed discussions and analyses of the latest scientific discoveries and advancements in molecular testing and targeted therapies for thoracic oncology. The expert faculty will focus on the clinical application of diagnostics, biomarkers, and various therapeutic agents, discussing how these tests and treatments can be effectively used to improve patient care.
Target Audience
- Medical Oncologists
- Surgeons
- Radiation Oncologists
- Pathologists
- Oncology Fellows
- Oncology Nurses
- Nurse Practitioners
- Physician Assistants
- Pharmacists
Organizing Committee
Conference Director:
Binay Shah, MD, MHA - Binaytara Foundation
Conference Co-Chairs:
Raid Aljumaily, MD - OU Health
Abdul Rafeh Naqash MD - OU Health
Learning Objectives
At the conclusion of the activity, participants will be able to:
- Review the various actionable molecular abnormalities in lung cancer and learn about the appropriate testing and treatment strategies for these alterations.
- Summarize the efficacy and potential toxicities of immune checkpoint inhibitors, targeted therapies, and other chemotherapy agents in the management of lung cancer.
- Identify the role of perioperative systemic therapy options in curative-intent treatment of non-small cell lung cancer (NSCLC), including chemotherapy, immune checkpoint inhibitors, and targeted therapies.
- Apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with lung cancer.
Friday, March 21st, 2025
All times are listed in Central Daylight Time (CDT)
07:00 AM – 07:30 AM Registration, Breakfast, & Exhibits
07:30 AM – 08:00 AM Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Justine Kam
08:00 AM – 08:55 AM Session 1 - Pathology, Genetics, and Biomarkers
Session Chair: Firas Jafri, MD & Gregory A. Parker, MD
08:00 AM – 08:10 AM Pathological Classification of Thoracic Neuroendocrine Tumors / Carcinoma, Clinical Implications and Emerging Biomarkers - Asrar Alahmadi, MD
08:10 AM – 08:20 AM ctDNA in Early and Late Stage Disease - Philip W. Mack, MD
08:20 AM – 08:30 AM Genomics and Biomarkers: Thoracic Oncology in 2024 - Amin Nassar, MD
08:30 AM – 08:55 AM Panel Discussion - Abdul Rafeh Naqash, MD; Naoko Takebe MD, PhD; Timothy Allen, MD
08:55 AM – 09:45 AM Break & Exhibits
09:45 AM – 10:30 AM Session 2 - Controversies in Thoracic Oncology
Session Chair: Hina A. Khan, MD
Debate: Locally Advanced NSCLC: Evolving Role of Trimodality Therapy
09:45 AM – 09:55 AM Upfront Neoadjuvant Therapy Followed by Surgery - Kaushal Parikh, MD, MBBS
09:55 AM – 10:05 AM Perioperative therapy and surgery - Raid Aljumaily, MD
10:05 AM – 10:30 AM Panel Discussion - Jess Schwartz, MD, FACS, FCCP
10:30 AM – 11:15 AM Session 3 - Understanding and Managing Anticancer Therapy-Related Pneumonitis
Session Chair: Naoko Takebe, MD
10:30 AM – 10:40 AM ADC Lung Toxicty: The Knowns and Unknowns and Where We Stand - Maida Hafiz, MD
10:40 AM – 10:50 AM MultiD Care ICI Pneumonitis and Emerging Therapeutic Approaches - Kevin Ho, MD
10:50 AM – 11:15 AM Panel Discussion - Debra Richardson, MD, FACS, FACOG
11:15 AM – 12:30 PM Session 4 - Frontline Therapy in Lung Cancer
Session Chair: Nirmal Choradia, MD
Debate: Frontline Therapy in Lung Cancer - EGFR
11:15 AM – 11:25 AM More is Better - Hina A. Khan, MD
11:25 AM – 11:35 AM More is NOT Better - Tejas Patil, MD
Debate: Frontline Therapy in Lung Cancer - Immunotherapy
11:35 AM – 11:45 AM More is Better: Dual Immune Checkpoint Inhibition and Quad Regimens - Biagio Ricciuti, MD
11:45 AM – 11:55 AM More is NOT Better: Triplet and Single Agent IO is the Standard - Nirmal Choradia, MD
11:55 AM – 12:30 PM Panel Discussion - Amy Eberle, APRN-CNS
12:30 PM – 01:30 PM Lunch & Exhibits
01:30 PM – 02:25 PM Session 5 - Current Standards and Emerging Therapies
Session Chair: Bruna Pellini, MD
01:30 PM – 01:40 PM NSCLC: Updates in immunotherapy for locally advanced unresectable tumors - Eric K. Singhi, MD
01:40 PM – 01:50 PM NSCLC: Used of targeted therapies in early stage. Updates and emerging strategies - Fawzi Abu Rous, MD
01:50 PM – 02:00 PM Small Cell Lung Cancer: Novel Biological Insights, Newly Approved Therapies and Emerging Targets - Abdul Rafeh Naqash, MD
02:00 PM – 02:25 PM Panel Discussion - Abdul Rafeh Naqash, MD; Hassan Kaleem, MD
02:25 PM – 02:40 PM Break & Exhibits
02:40 PM – 03:55 PM Session 6 - Rapid Reviews
Session Chair: Hassan Kaleem, MD
02:40 PM – 02:50 PM Emerging Biospecifics and ADCs in Lung Cancer - Sonam Puri, MD
02:50 PM – 03:00 PM ALK, HER2, ROS, RET, and MET in 2024 - Ashtin Taylor, PharmD
03:00 PM – 03:10PM Post -Targeted Therapy Landscape in NSCLC - Yasir El-Amin, MD
03:10 PM – 03:20 PM How I Approach Oligometastatic Disease - Steven Lin, MD
03:20 PM – 04:00 PM Panel Discussion - Clay Thomas Reed, MD
04:00 PM Adjourn
HOTEL INFORMATION
Coming Soon ..
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Jess Schwartz
Raid Aljumaily, MD
Abdul Rafeh Naqash, MD
Nirmal Choradia, MD, MPH
Firas Jafri, MD
Hassan Kaleem, Hematologist Oncologist
Bruna Pellini, MD- Medical Oncologist, Assistant Member, Department of Thoracic Oncology, Moffitt Cancer Center
Fawzi Abu Rous, MD
Asrar AlAhmadi, MBBS. MAS-CR
Maida Hafiz
Kevin Ho, MD
Hassan Kaleem, Hematologist Oncologist
Amin Nassar, MD
Kaushal Parikh, MD
Tejas Patil, MD
Biagio Ricciuti, MD, PhD
Debra Richardson
Eric Singhi, Eric K. Singhi, MD
Ashtin Taylor, PharmD
Acknowledgement of Commercial Support
This activity is supported with an Independent Medical Education grant from Johnson & Johnson.
Available Credit
- 6.00 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 6.00 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 6.00 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.